UKINETS2021 19th Annual Meeting of the UK and Ireland Neuroendocrine Tumour Society 2021 Oral Communications (3 abstracts)
An update on the effects of debulking surgery and liver directed intra-arterial therapies on quality of life in patients with metastatic neuroendocrine tumours
Eleanor Woods 1 , Adam Sinclair 2 , Emma Jarvis 1 , Emma Ramsey 1 , Lulu Tanno 1 , Salma Naheed 1 , Thomas Armstrong 1 , Arjun Takhar 1 , John Knight 1 , Brian Stedman 1 , Sachin Modi 1 , Timothy Bryant 1 , David Breen 1 , Luke Nolan 1 , Ma’en Al-Mrayat 1 , Neil Pearce 1 & Judith Cave 1
1University Hospital Southampton, Southampton, United Kingdom; 2University of Southampton, Southampton, United Kingdom
Background: Neuroendocrine tumours (NETs) arise from neuroendocrine cells, they are commonly found in the pancreas, small bowel and lung. They are a heterogeneous group of tumours capable of secreting a variety of hormones, therefore the spectrum of symptoms is broad. Treatment options for metastatic NETs include cytoreductive surgery, or interventional radiology procedures such as transarterial embolization (TAE).
Aims: Previous studies have shown that debulking surgery for patients with functional NETs can reduce symptom burden. This study aimed to explore the effect that cytoreductive surgery and liver directed therapies had on quality of life (QOL) over a two-year period for patients with functioning and non-functioning NETs. The secondary aim was to investigate how long it takes for patients to recover QOL post intervention.
Methods: The study was a non-interventional prospective cohort study carried out at a single site; patients received treatment according to routine practice of the clinical team. Participants filled out two QOL assessments (EORTC QLQ-GINET21, EORTC QLQ-C30 V3) and one health status questionnaire (EQ-5D-3L) at pre-op, post-op and then 3 monthly for two years.
Results: 22 participants were included in the study, 19 of these completed over 60% of the follow up questionnaires, the median age was 69. 16 patients were treated with debulking surgery, and 6 received liver directed therapy. We have already shown that QOL dips after treatment but returns to above baseline at 3 months. [1] We will present the full 2 year follow up for all patients, exploring long term QOL outcomes after these palliative procedures. This will provide real world data for counselling on these interventions, enabling patients to make informed decisions about treatment, and provide a realistic view of the post-procedure recovery period and the two years that follow.
References: 1. Sinclair A, Tanno L, Jarvis E, Ramsey E, Naheed S, Armstrong T, Takhar A, Knight J, Stedman B, Modi S, Bryant T, Breen D, Nolan L, Al-Mrayat M, Pearce N, Cave J, The effects of debulking surgery, transarterial embolisation and transarterial chemoembolisation, on quality of life (QOL) in patients with metastatic ileal and pancreatic neuroendocrine tumours, [Poster] UKINETS conference 2nd December 2019, Birmingham UK.
Volume 80
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more